Primary Cells Market in terms of revenue was estimated to be worth $1.7 billion in 2023 and is poised to reach $2.8 billion by 2028, growing at a CAGR of 10.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growth of this market can be attributed to factors such as the is government investments for cell-based research, rising growth in pharmaceutical & biotechnology industries, increasing cancer research, increasing demand for monoclonal antibodies, increasing demand for personalized medicine, and growing advantages of primary human cells over cell lines.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32854960

human primary cells segment accounted for the dominant share of the primary cells market, by origin.”

On the basis of origin, the primary cells market is categorized into animal and human primary cells. In 2022, the human primary cells segment accounted for the largest share of the primary cells market. Factors responsible for the growth of the segment include the demand for accurate disease models, increasing application in studying cancer stem cells and drug-drug interactions in cancerous cells and circulating tumor cells, increasing the burden of chronic diseases, safety testing requirements, and ethical considerations.

“Hematopoietic cells segment accounted for the largest share in the primary cells market, by type.”

On the basis of type, the primary cells market is divided into hematopoietic cells, dermatocytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells. Hematopoietic cell transplants are frequently used to develop novel cancer therapies to treat blood cancers and other disorders of the immune system. Hematopoietic cells are also used to study the biochemical pathways of tumor cells and the efficacy of different drugs. This wide range of applications will contribute to the largest share of the hematopoietic cells in the primary cells market in 2022.

the pharmaceutical & biotechnology companies, and CROs segment accounted for the largest share of the global primary cells market, by end user.”

On the basis of end users, the primary cells market is segmented into pharmaceutical & biotechnology companies, and CROs, academic & research institutes, and other end users. In 2022, pharmaceutical & biotechnology companies and CROs accounted for the largest share of the primary cells market, mainly due to the high adoption of primary cells among pharmaceutical & biotechnology companies and CROs for cell-based experiments and cancer research.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=32854960

North America is the largest regional market for primary cells.”

The global primary cells market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2022, North America accounted for the largest share of the primary cells market. The increasing number of players launching new human primary cells for research, expansion in the pharmaceutical and biotechnology industries, rising incidences of cancer and various other chronic and infectious diseases, and the growing focus on R&D in the region are the major factors driving the growth of the North American market. As life science research studies have significant use of primary cells, the growing focus on R&D in this field is expected to drive market growth in North America during the forecast period.

Key Market Players:

Key players in the primary cells market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza Group (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), HemaCare Corporation (US), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), Corning Incorporated (US), AllCells (US), American Type Culture Collection (US), Axol Bioscience Ltd. (UK), iXCells Biotechnologies (US), Neuromics (US), StemExpress (US), BioIVT (US), ScienCell Research Laboratories, Inc. (US), ProMab Biotechnologies, Inc. (US), Creative Bioarray (US), BPS Bioscience, Inc. (US), Epithelix (Switzerland), ReachBio LLC (US), AcceGen (US), AMSBIO (UK), and Kosheeka (India).

Primary Cells Market – Report Highlights:

• Market sizes are updated for the base year 2022 and forecasted from 2023 to 2028.
• The impact of the recession on year-on-year growth during the forecast period (2023 to 2028) has also been considered.
• Market Challenge, Regulatory analysis, technology analysis, Porter’s five forces analysis, key conferences & events in 2023–2024, key stakeholders, and buying criteria have been added to the market overview chapter.
• The market evaluation framework, market share analysis, and competitive leadership mapping have been updated in the competitive landscape chapter of the report. The current version of the report includes the revenue share analysis of key market players from 2020 to 2022.
• The updated competitive leadership mapping is an output of a comprehensive study of the key vendors offering tangential flow filtration products. The top 25 vendors were shortlisted from a list of 50+ vendors, and these were evaluated based on the market share/ranking and product footprint, rated and positioned on a 2×2 quadrant, referred to as Company Evaluation Quadrant, categorizing them as ‘Star,’ ‘Emerging Leader,’ ‘Pervasive,’ and ‘Emerging Companies.’
• In the updated competitive leadership mapping of key startup vendors offering primary cell products, the top 10 vendors were shortlisted from a list of 50+ vendors. These were evaluated based on the market share/ranking and product footprint, rated and positioned on a 2×2 quadrant, referred to as Competitive Leadership Quadrant, categorizing them as ‘Progressive Companies,’ ‘Starting Blocks,’ ‘Responsive Companies,’ and ‘Dynamic Companies.
• The current edition of the report provides updated financial information till the financial year ended on 31st March 2022 (depending on availability) for each listed company in a graphical representation. This will help in the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating region/country, and business segment focus in terms of the highest revenue-generating segment.
• Recent developments are helpful in understanding market trends and growth strategies adopted by players in the market. In this market, the number of product launches has increased in the last three years (January 2020 to June 2023).
• Tracking the product portfolios of prominent market players helps to analyze the products in the cell isolation market. The new edition of the report provides an updated product portfolio of the companies profiled in the report.
• The End User segment is modified in the current edition of the report. The End Users considered for the report are pharmaceutical & biotechnology companies, and CROs, Academic & research institutes, and other end users.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=32854960